TYK Medicines, Inc. will convene its first extraordinary general meeting of 2026 on 15 July 2026 at 2:00 p.m. in Shanghai. The sole agenda item is a special resolution authorizing the Board to issue additional H-shares—whether through new allotments or the sale of treasury shares—up to 20% of the Company’s total issued share capital (excluding treasury shares) as of the meeting date.

If the Company has previously repurchased shares, those repurchased shares may be added to the number available for re-issuance under the mandate. For any cash placements or public offerings executed under this authority, the issue price may not be set at a discount of 20% or more to the benchmark price defined by Hong Kong Listing Rule 13.36.

The mandate, once approved, will remain effective until the earliest of three events: 1) 12 months after the EGM approval date, 2) the conclusion of the 2026 annual general meeting, or 3) the date on which shareholders revoke or vary the resolution.

To determine eligibility to vote, the H-share register will be closed from 10 July 2026 to 15 July 2026 (both days inclusive). Share transfer documents must be lodged with Computershare Hong Kong Investor Services Limited by 4:30 p.m. on 9 July 2026. Proxy forms must be submitted no later than 2:00 p.m. on 14 July 2026.

In accordance with Hong Kong Listing Rule 17.05A, the trustee of the Company’s share incentive scheme will abstain from voting the 1.48 million shares it holds on trust. Voting at the EGM will be conducted by poll.